Monti J M
Department of Pharmacology & Therapeutics, School of Medicine, Clinics, Hospital, Montevideo, Uruguay.
Br J Psychiatry Suppl. 1989 Oct(6):61-5.
The effect of moclobemide, a short-acting, reversible, preferential monoamine oxidase-A inhibitor in a 4-week therapeutic trial, on the sleep of ten depressed patients, was assessed by polysomnographic recordings. Compared with their time on placebo, patients receiving moclobemide showed improved sleep continuity, particularly during the intermediate and late stages of drug administration. The total increase in sleep time was comprised of larger amounts of stage 2 non-rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep. Withdrawal of moclobemide was followed by a further increase of REM sleep, although values did not surpass those sometimes observed in adults with normal sleep. In these patients, the symptoms of depression were rated as being significantly improved during the study period.
通过多导睡眠图记录，评估了短效、可逆、选择性单胺氧化酶 -A抑制剂吗氯贝胺在一项为期4周的治疗试验中对10名抑郁症患者睡眠的影响。与服用安慰剂期间相比，服用吗氯贝胺的患者睡眠连续性有所改善，尤其是在药物治疗的中期和后期。睡眠时间的总体增加包括较多的2期非快速眼动（NREM）睡眠和快速眼动（REM）睡眠。停用吗氯贝胺后，REM睡眠进一步增加，尽管数值未超过正常睡眠成年人有时观察到的数值。在这些患者中，抑郁症状在研究期间被评为有显著改善。
